{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7950","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.7","upperLimit":"77.3","value":"64.7"},{"groupId":"OG001","lowerLimit":"44.8","upperLimit":"66.4","value":"56.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Survival rates are estimated using the Kaplan-Meier method. The protocol specifies that the distributions of survival times be compared between the arms, which is reported in the statistical analysis results. Two-year rates are provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"60 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel.","id":"OG000","title":"Standard Radiation Therapy"},{"description":"A maximum of 80.4 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel. Radiation therapy dose is individualized for final 9 fractions based on imaging results from PET/CT scan between fractions 18 and 19.","id":"OG001","title":"Adaptive Radiation Therapy"}],"paramType":"NUMBER","populationDescription":"Eligible participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up: weekly during treatment, then 1, 3, 6, 9, 12, 18, 24, 30, 36, 48, and 60 months after end of protocol treatment, then annually. Maximum follow-up at time of reporting was 7.3 years. Two-year rates reported here.","title":"Percentage of Participants Alive (Overall Survival) (NRG)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}